Education
About Us
Working with TipRanks
Follow Us
4basebio UK Societas (GB:4BB)
LSE:4BB
4BB Stock Chart & Stats
615.00p
25.00p(2.04%)
At close: 4:00 PM EST
615.00p
25.00p(2.04%)
Day’s Range― - ―
52-Week Range520.00p - 1,220.00p
Previous CloseN/A
Volume812.00
Average Volume (3M)999.00
Market Cap
£85.17M
Enterprise Value70.00M
Total Cash (Recent Filing)£26.11M
Total Debt (Recent Filing)£15.44M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)6.02
Price to Sales (P/S)170.11
P/FCF Ratio-12.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.97
Revenue Forecast (FY)£7.00M
Bulls Say, Bears Say
Bulls Say
GMP PDNA Manufacturing4basebio provides GMP-grade plasmid DNA, a critical upstream input for gene therapies, cell therapies and vaccines. Owning core manufacturing capability anchors long-term customer relationships, creates high switching costs, and positions the company to capture secular growth in genetic medicine supply chains.
Strong Recent Revenue GrowthNearly 200% reported revenue growth reflects accelerating commercial traction and growing demand for pDNA services. Sustained top-line expansion over multiple quarters would support capacity utilization, improve operating leverage potential, and validate the business model to long-term clients and partners.
Improved Equity PositionThe transition from negative to positive shareholders' equity and a stated strong equity position reduces insolvency risk and strengthens the capital base. This improvement enhances ability to raise growth capital on better terms and supports investment in scale-up of manufacturing capabilities.
Bears Say
Persistent LossesOngoing negative net and EBIT margins indicate the company has not yet converted revenue into sustainable profitability. Over the medium term, continued operating losses erode cash reserves, limit reinvestment ability, and force reliance on external funding unless margins improve through scale or cost control.
Negative Operating Cash FlowConsistent negative operating and free cash flow shows core operations are not self-financing, requiring external financing to fund growth. Dependence on financing raises dilution and liquidity risk and constrains resilience if capital markets tighten or fundraising terms worsen.
Moderate LeverageA moderate debt-to-equity ratio increases fixed obligations and financial risk, especially given negative cash flows and losses. Leverage can limit strategic flexibility, increase interest burden, and amplify vulnerability to adverse operational or funding shocks absent sustained profit improvement.
4basebio UK Societas News
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 520.00p and its highest was 1220.00p in the past 12 months.
What is 4basebio UK Societas’s market cap?
4basebio UK Societas’s market cap is £85.17M.
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is Sep 25, 2026 which is in 210 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on Sep 29, 2025. The company reported -0.5p earnings per share for the quarter, missing the consensus estimate of N/A by -0.5p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Overvalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 15,538,518 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.5p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.69%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4basebio UK Societas Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.99%
12-Months-Change
Fundamentals
Return on Equity
-209.34%
Trailing 12-Months
Asset Growth
209.11%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---